Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Basilea Pharmaceutica AG
PK5Current price
32.6 EUR
0 EUR (0.00%)
Last closed
42.8 CHF
Company
www.basilea.com
ISIN
CH0011432447
Sector
Healthcare
Industry
Biotechnology
Exchange
Stuttgart Exchange
Capitalization
543 141 122 CHF
Yield for 12 month
+17.23 %
1Y
3Y
5Y
10Y
15Y
PK5
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
57.69 CHFP/E ratio
–Dividend Yield
–Current Year
+157 491 867 CHF
Last Year
+147 631 765 CHF
Current Quarter
+76 224 209 CHF
Last Quarter
+72 663 423 CHF
Current Year
+130 722 026 CHF
Last Year
+120 852 933 CHF
Current Quarter
+24 554 840 CHF
Last Quarter
+55 880 569 CHF
Key Figures PK5
1 year
3 years
5 years
10 years
EBITDA
-5 591 454 CHF
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-2.05 %
PEG Ratio
–
Return On Equity TTM
-4.1 %
Wall Street Target Price
57.69 CHF
Revenue TTM
148 887 632 CHF
Book Value
1.38 CHF
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-10.1 %
Dividend Yield
–
Gross Profit TTM
49 313 496 CHF
Earnings per share
-0.07 CHF
Diluted Eps TTM
-0.07 CHF
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-33.2 %
Profit Margin
-0.44 %
Dividend Analytics PK5
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PK5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
11.04.2013
Forward Annual Dividend Yield
–
Last Split Factor
1039:1029
Payout Ratio
–
Last Split Date
13.03.2007
Dividend Date
–
Stock Valuation PK5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
10.6952
Enterprise Value Revenue
3.9801
Price Sales TTM
3.648
Enterprise Value EBITDA
24.279
Price Book MRQ
32.3841
Financials PK5
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PK5
For 52 weeks
31.97 CHF
47.91 CHF
50 Day MA
45.28 CHF
Shares Short Prior Month
–
200 Day MA
40.54 CHF
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart